![]() Contact us Contact should be directed to the following: Business inquiries: Managing Director, Gunnar Sælid Scientific matters: Business development: Anders Fugelli, PhD Company head office: Oslo office: E-mail: post@lytixbiopharma.com |
![]() September 01, 2010:
- Approval to start Phase IIa clinical trial with Lytixar™ (LTX-109)Oslo, Norway and Seoul, Korea, June 09, 2010:
- Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trialMay 20, 2010:
- Update on the Phase I clinical trials of Oncopore™ (LTX-315) for the treatment of cancer.May 20, 2010:
- Approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial |
|||||||||


